Lyra Therapeutics Inc (NAS:LYRA)
$ 0.1806 0.0083 (4.82%) Market Cap: 11.28 Mil Enterprise Value: -5.02 Mil PE Ratio: 0 PB Ratio: 0.55 GF Score: 39/100

Lyra Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 14, 2022 / 04:00PM GMT
Release Date Price: $6.01 (-2.28%)
Unidentified Analyst H.C. Wainwright;Analyst

Good afternoon, everyone, and thank you for joining H.C. Wainwright's 24th Annual Global Investment Conference. I'm Jennifer (inaudible), an associate at H.C. Wainwright. And I'd like to introduce our presenter, Maria Palasis of Lyra Therapeutics.

Maria Palasis
Lyra Therapeutics, Inc. - President and CEO

Thank you, Jennifer, and thank you for the invitation to present today. It's an exciting time for Lyra. We are in our pivotal program currently. Our first indication is for chronic rhinosinusitis. It's an enormous unmet need with millions of patients. 10% of the US population have this disease. And our product is a drug delivery system that uses a known anti-inflammatory drug, which we view as highly de-risked. This is our disclaimer. It's also on our website.

So Lyra has developed a platform that is able to target drugs directly to tissues in a very consistent way, which enables us to treat chronic diseases. Our first indication is for chronic rhinosinusitis. These are patients that have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot